Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Seasonal Allergic Rhinitis. According to GlobalData, Phase II drugs for Seasonal Allergic Rhinitis have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dupilumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody developed based on VelocImmune technology. It is formulated as an injectable solution for subcutaneous route of administration. Dupilumab is indicated for the treatment of asthma, atopic dermatitis (atopic eczema), nasal polyps (nasal polyposis). Dupixent is indicated for the treatment of adults and pediatrics patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
It is under development for the treatment of , grass pollen allergy, gastroenteritis, chronic urticaria or hives, dermatitis (eczema), prostate cancer, chronic obstructive pulmonary disease (copd), chronic bronchitis, alopecia areata, bullous pemphigoid, prurigo, systemic sclerosis (scleroderma), pruritus, allergic bronchopulmonary aspergillosis, atopic keratoconjunctivitis, asthma, immunoglobulin g4-related disease (igg4-rd), atopic dermatitis (atopic eczema), eosinophilic gastritis with or without eosinophilic duodenitis and ulcerative colitis.
It was under development for peanut allergy and rhinosinusitis.
Regeneron Pharmaceuticals overview
Regeneron Pharmaceuticals (Regeneron) is engaged in discovering, developing, manufacturing, and marketing medicines for the treatment of serious medical conditions. Its products are focused on helping patients suffering from cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, hematologic conditions, pain, and rare diseases. It develops products using its Trap and VelociSuite technology platforms, which include VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, and other related technologies. The company operates manufacturing facilities in Rensselaer, New York, and Limerick, Ireland. It also collaborates with strategic partners to develop, manufacture, and commercialize its products. It sells its products to specialty pharmacies and distributors. The company operates in the US, the Netherlands, Bermuda, Ireland, Spain, India, Japan, and the UK. Regeneron is headquartered in Tarrytown, New York, the US.
For a complete picture of Dupilumab’s drug-specific PTSR and LoA scores, buy the report here.